STTK · Shattuck Labs, Inc.

Current Thesis

Shattuck Labs' receptor-blocking antibody story now depends on translating healthy-volunteer results into Crohn's disease efficacy; the near-term market test is recovery above the September 4 reference close before the published downside threshold breaks. SL-325 blocks death receptor 3 (DR3), the receptor for the inflammatory protein TL1A. The June 8, 2026 Phase 1 release reported complete receptor occupancy at doses of 0.1 mg/kg and higher, but supplied no patient efficacy result. June 8 company release

The material change since September 5 is operational: in the September 8 conference transcript, management described RECEPTIVE-CD1 as open. That advances the earlier trial-start story, although the statement does not establish a first-patient dosing date. Management placed induction results in the first half of 2028. September 8 management transcript

The lifecycle assessment is an inference: the narrative is maturing — the trial has advanced according to management, while the September 18 reference close of $6.01 is below September 4's $6.79. The near-term recovery case succeeds on a weekly close above $6.79 before a weekly close below $5.75; neither outcome establishes clinical efficacy.

Bullish and bearish views on Shattuck Labs, Inc.

The model's bull view on Shattuck Labs, Inc. (STTK), in brief: Human target engagement is measured. The June 8, 2026 release reported complete DR3 occupancy at doses of 0.1 mg/kg and higher. This supports biological activity, while patient benefit remains unmeasured. Phase 1 release Cash supports the development plan. Shattuck reported… The bear view: The sample cannot establish superiority. Both cases follow in full.

Bull Case

• Human target engagement is measured. The June 8, 2026 release reported complete DR3 occupancy at doses of 0.1 mg/kg and higher. This supports biological activity, while patient benefit remains unmeasured. Phase 1 release
• Cash supports the development plan. Shattuck reported $208.3 million in cash, cash equivalents and short-term investments at June 30, 2026. Management's August 11 guidance extended funding into 2029, excluding additional capital or business-development proceeds; that is a forecast, not guaranteed funding sufficiency. Second-quarter release

Bear Case

• The sample cannot establish superiority. The June 8 trial enrolled 72 healthy volunteers and reported anti-drug antibodies in 3.7% of treated participants. This sample and design cannot establish superior immunogenicity or efficacy against competing antibodies in Crohn's disease. Phase 1 release
• Spending increased before patient proof. Research and development expense reached $11.7 million in the second quarter of 2026, versus $8.7 million in the second quarter of 2025, according to the August 11 release. Those expenses document development activity, not clinical success. Second-quarter release

Setup & Price Structure

The September 18, 2026 adjusted reference close was $6.01, with a three-month price gain of 14.7% and a reported distance of 25.4% below the $8.06 trailing annual high. The 14-period relative strength index (RSI) was 18.4. These supplied market observations show weak recent momentum; they do not establish a reversal.

September 4's $6.79 public close supplies the recovery reference. The $5.75 threshold retains the September 5 published thesis boundary; the available observations do not establish it as repeatedly tested support. The evidence supports low conviction in recovery before that boundary breaks.

Coverage is observable, but crowding is not established. Benzinga reported HC Wainwright's $14 analyst target on August 11 and Raymond James' $18 initiation target on August 24. The September 18 close remained below the September 4 close despite those earlier endorsements. Short-interest, fund-flow and moving-average measurements are missing, so these observations cannot identify positioning or selling pressure.

Catalyst Calendar (next 30 days)

• 2026-09-30 — Earlier guidance window ends. The August 11 release guided trial initiation during the third quarter. Management's September 8 statement that the study was open means this date no longer represents an untouched initiation binary; absence of another press release alone would not establish failure. September 8 management transcript

No additional company-confirmed event date was established for September 20–October 20, 2026. The clinical decision point lies later: management's September 8 guidance placed induction results in the first half of 2028, without an exact release date. Management transcript

What Would Change Our Mind

Failure to preserve the September 5 published price boundary would end the near-term recovery thesis: a weekly close below $5.75 invalidates it. A weekly close above the September 4 reference close of $6.79 beforehand completes the defined recovery case. These are research conditions, not evidence that SL-325 works in patients.

The biological hypothesis requires a separate test. Failure of RECEPTIVE-CD1 to meet its primary endoscopic-response endpoint would contradict the proposed translation from receptor occupancy to patient benefit; management identified that endpoint in its September 8 discussion. Management transcript

Correlation Notes

This is a single-company setup. The September 18 price observations provide no paired peer or biotechnology-index return series, so no measured correlation or group-supported recovery claim is justified. The June 8 DR3-occupancy result identifies the scientific exposure, but it cannot establish how STTK responds to another company's clinical announcement.